Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Translational Development Acquisition (TDAC) Change in Accured Expenses (2024 - 2026)

Translational Development Acquisition's Change in Accured Expenses history spans 3 years, with the latest figure at -$12988.0 for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 114.09% to -$12988.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$76154.0, a N/A change, with the full-year FY2025 number at $29008.0, up 106.45% from a year prior.
  • Change in Accured Expenses came in at -$12988.0 for Q1 2026, down from -$8772.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $92174.0 in Q1 2025, with the low at -$469542.0 in Q4 2024.
  • Historically, Change in Accured Expenses has averaged -$61817.4 across 3 years, with a median of -$8772.0 in 2025.
  • Biggest five-year swings in Change in Accured Expenses: soared 98.13% in 2025 and later tumbled 114.09% in 2026.
  • Year by year, Change in Accured Expenses stood at -$469542.0 in 2024, then surged by 98.13% to -$8772.0 in 2025, then tumbled by 48.06% to -$12988.0 in 2026.
  • Business Quant data shows Change in Accured Expenses for TDAC at -$12988.0 in Q1 2026, -$8772.0 in Q4 2025, and $8163.0 in Q3 2025.